# Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

> **NCT02408042** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Western Regional Medical Center**

## Conditions studied

- Lymphoma
- Hodgkin's Lymphoma
- Non-hodgkin's Lymphoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **DRUG:** Mesna
- **DRUG:** Carboplatin
- **DRUG:** Brentuximab vedotin
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02408042
- **Lead sponsor:** Western Regional Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02408042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02408042, "Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02408042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*